On May 12, 2025, Royalty Pharma plc held its Annual General and Special Meeting of Shareholders, where 15 proposals were voted on. Shareholders approved the Membership Interest Purchase Agreement, the 2025 Equity Incentive Plan, and authorized share repurchases. All nine director nominees were elected. Non-binding votes approved compensation for named executive officers and the UK remuneration reports. Ernst & Young was reappointed as both the U.S. and UK statutory auditor. The board was authorized to allot shares, including without pre-emption rights. All proposals received majority support.

ROYALTY PHARMA APPOINTS VLAD CORIC, M.D. TO BOARD OF DIRECTORS

NEW YORK, NY – Royalty Pharma plc (Nasdaq: RPRX) has announced the appointment of Vlad Coric, M.D., Chairman and CEO of Biohaven, to its Board of Directors, effective immediately.

Dr. Coric brings extensive experience in the biopharmaceutical industry, particularly in neuroscience, immunology and oncology. As the head of Biohaven, he led the company through significant milestones, including the FDA approval and launch of Nurtec ODT for migraine treatment and the submission of a New Drug Application for zavegepant, the first intranasal CGRP antagonist for migraine relief. His leadership was instrumental in Biohaven's growth and its eventual acquisition by Pfizer in 2022 for approximately $13 billion.

“I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric,” said Pablo Legorreta, founder and CEO of Royalty Pharma. “Vlad’s entrepreneurial approach and outstanding leadership skills, honed over a distinguished career in biopharma, will serve as tremendous assets to Royalty Pharma. In addition, Vlad brings notable experience in the royalty funding space, having completed multiple transactions with us during his tenure at Biohaven.”

Before his time at Biohaven, Dr. Coric held research and development roles at Yale School of Medicine and Bristol-Myers Squibb, working across a wide range of therapeutic areas. He is a graduate of Wake Forest University School of Medicine, where he earned his medical degree, and the University of Connecticut, where he studied neurobiology and physiology.